Építés alatt – nem éles oldal
Belépés

What researchers published on Máj- és epeúti rák

124 401 papers, newest first.

Showing 20 of 2405

  • Vizsgálati eredményCadonilimab combined with lenvatinib and transarterial chemoembolization for non-metastatic unresectable hepatocellular carcinoma: a multicenter, open-label, phase 2 study.BMC medicine
  • Vizsgálati eredményFMT combined with atezolizumab-bevacizumab in hepatocellular carcinoma refractory to immunotherapy: an open label, single-arm, phase II pilot study.Nature communications
  • Randomizált vizsgálatSpatial Acid-Associated Niches Inform Irinotecan-Based DEB-TACE in Colorectal Liver Metastases: A Multicentre Randomized Trial.Liver international : official journal of the International Association for the Study of the Liver
  • Vizsgálati eredményStudy protocol of a prospective, non-interventional cohort study evaluating the benefits of transjugular intrahepatic portosystemic shunt in patients with hepatocellular carcinoma receiving first-line atezolizumab plus bevacizumab (NISTIPS TRITICC-4, IKF092).Future oncology (London, England)
  • Vizsgálati eredményCobimetinib + Vemurafenib in Patients With BRAF V600E-Mutant Papillary Thyroid and Biliary Tract Cancers: Results From the TAPUR Study.JCO precision oncology
  • Vizsgálati eredményStudy protocol: a phase II study of trifluridine/tipiracil plus liposomal irinotecan as second-line therapy in advanced biliary tract cancer (TRITICC 2).BMC cancer
  • Vizsgálati eredményDUBHE-H-308 study protocol: rationale and adaptive design of a randomized, open-label, seamless phaseII/III trial of iparomlimab and tuvonralimab (QL1706)-based regimens versus sintilimab plus bevacizumab as first-line treatment for advanced hepatocellular carcinoma.Future oncology (London, England)
  • Randomizált vizsgálatComparison of Remimazolam and Propofol for Anesthesia Management in Liver Cancer Patients Undergoing Percutaneous Radiofrequency Ablation: A Randomized Controlled Trial.Drug design, development and therapy
  • Randomizált vizsgálatDisitamab vedotin for HER2-positive breast cancer with liver metastases: phase 3 results from the RC48-C006 phase 2/3 trial.Nature communications
  • Vizsgálati eredményOptimizing the Therapeutic Index: Sequential Intraarterial-Intravenous PRRT with Personalized Volumetric-Adjusted Dosing.Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • Randomizált vizsgálatTACE combined with apatinib versus TACE alone for unresectable hepatocellular carcinoma in China: a cost-effectiveness and budget impact analysis.BMJ open
  • Randomizált vizsgálatFive-Year Follow-Up of the Phase III ASCOT Trial of Adjuvant S-1 After Resection for Biliary Tract Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • Randomizált vizsgálatAn integrated Phase II/III randomized study comparing durvalumab and tremelimumab ± Hepatic ArteriaL infusion chemotherapy with GEMOX in hepatocellular Carcinoma with high tumor burdEn - ALICE (PRODIGE89 - UCGI44 - ALICE).Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • Vizsgálati eredményFOLFOX-based transarterial infusion chemotherapy for unresectable colorectal cancer: protocol of an open-label, multicentre, randomised, controlled, phase II trial.BMJ open
  • Randomizált vizsgálat'Posterior (SMA-first) Approach' Versus 'Standard Approach' in Terms of Resection Margin and Long-Term Survival After Pancreaticoduodenectomy for Periampullary and Pancreatic Carcinoma: A Randomized Trial.Journal of surgical oncology
  • Vizsgálati eredményAssociation between gut microbiota characteristics and therapeutic efficacy of multimodal combination therapy in hepatocellular carcinoma with portal vein tumor thrombus: a secondary analysis of a prospective phase II trial.Frontiers in immunology
  • Vizsgálati eredményIntegrated single-cell multi-omics characterization reveals lipid-associated macrophage-mediated immunosuppression in neoadjuvant immunotherapy of hepatocellular carcinoma.Nature communications
  • Randomizált vizsgálatLiver transplant allocation by milan criteria may exclude eligible HCC patients without survival benefit - a post-hoc analysis of the SiLVER study.Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • Vizsgálati eredményExtended Follow-up of Botensilimab plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer without Active Liver Metastases.Clinical cancer research : an official journal of the American Association for Cancer Research
  • Vizsgálati eredményImpact of endoscopic ultrasound in cholangiocarcinoma staging: a systematic review and meta-analysis.Endoscopy